Recently, Leadsynbio completed a RMB 450 million Pre-IPO financing round, with both new and existing investors participating in the round.

This financing reflects the capital market’s recognition of Leadsynbio’s ability to commercialize synthetic biology. The company has established a complete industrial chain spanning technology R&D, large-scale manufacturing, and global sales.

The proceeds will be primarily used for new product R&D and industrialization, increased market development efforts, and overall enhancement of competitiveness. The company will continue to strengthen its industrialization capabilities, expand its business scale and steadily grow into a globally influential biomanufacturing enterprise.